Sarepta Therapeutics Inc
XBER:AB3A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sarepta Therapeutics Inc
XBER:AB3A
|
US |
|
Nordex SE
F:NDX1
|
DE |
|
W
|
Warner Bros Discovery Inc
DUS:J5A
|
US |
|
C
|
Covestro AG
DUS:1COV
|
DE |
|
Ypsomed Holding AG
OTC:YPHDF
|
CH |
|
C
|
Canadian Tire Corporation Ltd
F:YAAA
|
CA |
|
Donear Industries Ltd
NSE:DONEAR
|
IN |
|
Harmony Gold Mining Company Ltd
F:HAM1
|
ZA |
Wall St Price Targets
AB3A Price Targets Summary
Sarepta Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AB3A is 28.793 EUR with a low forecast of 6.371 EUR and a high forecast of 50.337 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AB3A's stock price target?
Price Target
28.793
EUR
According to Wall Street analysts, the average 1-year price target for AB3A is 28.793 EUR with a low forecast of 6.371 EUR and a high forecast of 50.337 EUR.
What is the Revenue forecast for Sarepta Therapeutics Inc?
Projected CAGR
-12%
Over the last 13 years, the compound annual growth rate for Revenue has been 37%. The projected CAGR for the next 3 years is -12%.
What is the Gross Profit forecast for Sarepta Therapeutics Inc?
Projected CAGR
-8%
The compound annual growth rate for Gross Profit over the next 3 years is -8%.
